(By accessing, browsing or using the pages below, you agree to the Blog Conditions of Use/Disclaimer available under "Links.")
On August 9, 2019, Illinois Governor J.B. Pritzker signed into law Illinois Senate Bill 2023, which amends and makes permanent the State’s pilot medical cannabis program. The amendment will expand the number of patients who qualify for treatment under the program and include a social equity component. READ MORE
While some Missouri communities are welcoming access to medical cannabis, others may be more resistant and could look to zoning codes to restrict the establishment of cannabis businesses. Amendment 2 prohibits communities from flatly excluding medical cannabis businesses, but it does allow for some restrictions. READ MORE
With the passage of Amendment 2 by Missouri voters in November 2018, businesses will be able to apply for licenses to operate medical cannabis facilities in Missouri. While the date for businesses to apply for such licenses is still more than four months away, the timeline for starting the application process has already begun. READ MORE
On February 13, 2019, the Missouri Department of Health and Senior Services held a forum to hear suggestions regarding the drafting of preliminary medical cannabis regulations. Suggestions covered quality control and testing, fees and profits, startup logistics, distribution issues, and more. READ MORE
Three initiatives on Missouri’s November 6, 2018, ballot seek to make medical marijuana or medical cannabis legal under Missouri state law. In the second post in a series covering the initiatives, we detail the implications of each initiative for cannabis businesses. READ MORE
Three initiatives on Missouri’s November 6, 2018, ballot seek to make medical marijuana or medical cannabis legal under Missouri state law. In this first post in a series covering the initiatives, we detail the basic similarities and differences between each measure. READ MORE
Congress provided a sense of protection from DOJ enforcement to the medical cannabis industry through an updated version of the Rohrabacher-Farr Amendment. But the industry is still trying to interpret statements from the President and Attorney General that don’t provide any clearer picture about whether the federal government will leave the regulation of cannabis, at least medical cannabis, to the states. READ MORE
In a case of first impression in Arizona, the Court of Appeals in Green Cross Medical, Inc. v. Gally (April 18, 2017) held that a lease to operate a medical marijuana dispensary was not void from its inception, either under Arizona law or the federal Controlled Substances Act. READ MORE
More and more cities in California are allowing the once-banned delivery of medical marijuana directly to consumers. Learn about the latest developments statewide, including in Los Angeles. READ MORE
As the various state agencies look to draft rules and the timeline for implementation, we review the highlights of the new laws. READ MORE
Overall, industry experts are predicting that the size of the national market for legalized cannabis will exceed the November 2010 predictions of Harvard economist (and Cato Institute affiliate) Jeffrey Miron, who previously put the size of the marijuana market at $14 billion. READ MORE
Cannabis industry hopefuls in Illinois are poised to begin the application process after the three state agencies administering Illinois’ medical marijuana law released long-awaited metrics on Aug. 8. READ MORE
Thompson Coburn advises clients on state laws governing the business of cannabis to facilitate compliance with those state laws. Federal laws concerning cannabis currently conflict with state laws in states that have legalized cannabis or possession of cannabis. Although federal enforcement policy may at times defer to these states’ laws and not enforce conflicting federal laws, interested businesses and individuals should be aware that compliance with state law in no way assures compliance with federal law, and there is a risk that conflicting federal laws may be enforced in the future. In addition to this Cannabis-specific note, readers should review Thompson Coburn’s Conditions of Use / Disclaimers page containing other important information.
NOTICE.
Although we would like to hear from you, we cannot represent you until we know that
doing so will not create a conflict of interest. Also, we cannot treat unsolicited
information as confidential. Accordingly, please do not send us any information
about any matter that may involve you until you receive a written statement from
us that we represent you (an ‘engagement letter’).
By clicking the ‘ACCEPT’ button, you agree that we may review any information you transmit to us. You recognize that our review of your information, even if you submitted it in a good faith effort to retain us, and, further, even if you consider it confidential, does not preclude us from representing another client directly adverse to you, even in a matter where that information could and will be used against you. Please click the ‘ACCEPT’ button if you understand and accept the foregoing statement and wish to proceed.
